UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Robot-assisted nephroureterectomy for upper tract urothelial carcinoma: results from three high-volume robotic surgery institutions

Journal of robotic surgery, 2020-02, Vol.14 (1), p.211-219

2020

Volltextzugriff (PDF)

Continue Service Improvement at CERN Computing Centre

Journal of physics. Conference series, 2014-01, Vol.513 (6), p.62004-6

2014

Volltextzugriff (PDF)

Sensitization to Aspergillus fumigatus as a risk factor for bronchiectasis in COPD

International journal of chronic obstructive pulmonary disease, 2017-01, Vol.12, p.2629-2638

2017

Volltextzugriff (PDF)

Magritte au risque de la sémiotique

1999

Volltextzugriff (PDF)

Subnanowatt Carbon Nanotube Complementary Logic Enabled by Threshold Voltage Control

Nano letters, 2013-10, Vol.13 (10), p.4810-4814

2013

Volltextzugriff (PDF)

Elevated serum calprotectin (S100A8/A9) in patients with severe asthma

The Journal of asthma, 2022-06, Vol.59 (6), p.1110-1115

2022

Volltextzugriff (PDF)

The survival impact of neoadjuvant hormonal therapy before radical prostatectomy for treatment of high-risk prostate cancer

Prostate cancer and prostatic diseases, 2017-12, Vol.20 (4), p.407-412

2017

Volltextzugriff (PDF)

Can we use immunohistochemistry as predicting factor of successful treatment with intensified neoadjuvant treatment in high-risk prostate cancer: A subanalysis of the ARNEO trial

European urology, 2024-03, Vol.85, p.S62-S63

2024

Volltextzugriff (PDF)

P047 - Can we use immunohistochemistry as predicting factor of successful treatment with intensified neoadjuvant treatment in high-risk prostate cancer: A subanalysis of the ARNEO trial

European urology, 2024-03, Vol.85, p.S62-S63

2024

Volltextzugriff (PDF)

A0604 - Two-year Quality of Life (QoL) outcomes of the randomized phase II trial ARNEO: Neoadjuvant degarelix with or without apalutamide prior to radical prostatectomy for high-risk prostate cancer

European urology, 2024-03, Vol.85, p.S1517-S1518

2024

Volltextzugriff (PDF)

Two-year Quality of Life (QoL) outcomes of the randomized phase II trial ARNEO: Neoadjuvant degarelix with or without apalutamide prior to radical prostatectomy for high-risk prostate cancer

European urology, 2024-03, Vol.85, p.S1517-S1518

2024

Volltextzugriff (PDF)

Finals results in the safety and performance evaluation of a drop-in gamma probe for sentinel lymph node dissection in prostate cancer

European urology, 2023-02, Vol.83, p.S2003

2023

Volltextzugriff (PDF)

V093 - Finals results in the safety and performance evaluation of a drop-in gamma probe for sentinel lymph node dissection in prostate cancer

European urology, 2023-02, Vol.83, p.S2003-S2003

2023

Volltextzugriff (PDF)

Correlation between the location of the index tumour and the location of positive lymph nodes in high-risk prostate cancer – a monocentric positive lymph node mapping study

European urology, 2024-03, Vol.85, p.S1269-S1270

2024

Volltextzugriff (PDF)

A0426 - Correlation between the location of the index tumour and the location of positive lymph nodes in high-risk prostate cancer – a monocentric positive lymph node mapping study

European urology, 2024-03, Vol.85, p.S1269-S1270

2024

Volltextzugriff (PDF)

Three-year oncological outcomes of the randomized phase II trial ARNEO: Neoadjuvant degarelix with or without apalutamide prior to radical prostatectomy for high-risk prostate cancer

European urology, 2024-03, Vol.85, p.S1514

2024

Volltextzugriff (PDF)

P059 - Association between PSMA PET response and oncological outcome following neoadjuvant hormonal therapy in high-risk prostate cancer patients

European urology, 2024-03, Vol.85, p.S78-S79

2024

Volltextzugriff (PDF)

A0602 - Three-year oncological outcomes of the randomized phase II trial ARNEO: Neoadjuvant degarelix with or without apalutamide prior to radical prostatectomy for high-risk prostate cancer

European urology, 2024-03, Vol.85, p.S1514-S1514

2024

Volltextzugriff (PDF)

Association between PSMA PET response and oncological outcome following neoadjuvant hormonal therapy in high-risk prostate cancer patients

European urology, 2024-03, Vol.85, p.S78-S79

2024

Volltextzugriff (PDF)

The role of nuclear export in primary high-risk prostate cancer: A genomic analysis identifies XPO1 as potential therapeutic agent in high risk prostate cancer

European urology, 2021-06, Vol.79, p.S610

2021

Volltextzugriff (PDF)

Be-RALP study: The effect of adjuvant treatment on quality of life, erectile function and continence

European urology, 2021-06, Vol.79, p.S1647-S1648

2021

Volltextzugriff (PDF)

Ion feedback suppression in time projection chambers

Nuclear instruments & methods in physics research. Section A, Accelerators, spectrometers, detectors and associated equipment, 2006-05, Vol.560 (2), p.269-277

2006

Volltextzugriff (PDF)

PEACE V–Salvage Treatment of oligorecurrent nodal prostate cancer metastases (STORM): 24-months toxicity results of a randomized phase II trial

European urology, 2024-03, Vol.85, p.S1581-S1582

2024

Volltextzugriff (PDF)

A0644 - PEACE V–Salvage Treatment of oligorecurrent nodal prostate cancer metastases (STORM): 24-months toxicity results of a randomized phase II trial

European urology, 2024-03, Vol.85, p.S1581-S1582

2024

Volltextzugriff (PDF)

Ambient-Processable High Capacitance Hafnia-Organic Self-Assembled Nanodielectrics

Journal of the American Chemical Society, 2013-06, Vol.135 (24), p.8926-8939

2013

Volltextzugriff (PDF)

1 – 25 von 155

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(114)
Mit Volltextzugriff
(139)

Publikationsform

Sprache

Erscheinungsjahr

n.n

Neu hinzugefügt

... seit 90 Tagen
(1)

Menü

Weitere Dienste

Einstellungen

Robot-assisted nephroureterectomy for upper tract urothelial carcinoma: results from three high-volume robotic surgery institutions

Continue Service Improvement at CERN Computing Centre

Sensitization to Aspergillus fumigatus as a risk factor for bronchiectasis in COPD

Magritte au risque de la sémiotique

Subnanowatt Carbon Nanotube Complementary Logic Enabled by Threshold Voltage Control

Elevated serum calprotectin (S100A8/A9) in patients with severe asthma

The survival impact of neoadjuvant hormonal therapy before radical prostatectomy for treatment of high-risk prostate cancer

Can we use immunohistochemistry as predicting factor of successful treatment with intensified neoadjuvant treatment in high-risk prostate cancer: A subanalysis of the ARNEO trial

P047 - Can we use immunohistochemistry as predicting factor of successful treatment with intensified neoadjuvant treatment in high-risk prostate cancer: A subanalysis of the ARNEO trial

A0604 - Two-year Quality of Life (QoL) outcomes of the randomized phase II trial ARNEO: Neoadjuvant degarelix with or without apalutamide prior to radical prostatectomy for high-risk prostate cancer

Two-year Quality of Life (QoL) outcomes of the randomized phase II trial ARNEO: Neoadjuvant degarelix with or without apalutamide prior to radical prostatectomy for high-risk prostate cancer

Finals results in the safety and performance evaluation of a drop-in gamma probe for sentinel lymph node dissection in prostate cancer

V093 - Finals results in the safety and performance evaluation of a drop-in gamma probe for sentinel lymph node dissection in prostate cancer

Correlation between the location of the index tumour and the location of positive lymph nodes in high-risk prostate cancer – a monocentric positive lymph node mapping study

A0426 - Correlation between the location of the index tumour and the location of positive lymph nodes in high-risk prostate cancer – a monocentric positive lymph node mapping study

Three-year oncological outcomes of the randomized phase II trial ARNEO: Neoadjuvant degarelix with or without apalutamide prior to radical prostatectomy for high-risk prostate cancer

P059 - Association between PSMA PET response and oncological outcome following neoadjuvant hormonal therapy in high-risk prostate cancer patients

A0602 - Three-year oncological outcomes of the randomized phase II trial ARNEO: Neoadjuvant degarelix with or without apalutamide prior to radical prostatectomy for high-risk prostate cancer

Association between PSMA PET response and oncological outcome following neoadjuvant hormonal therapy in high-risk prostate cancer patients

The role of nuclear export in primary high-risk prostate cancer: A genomic analysis identifies XPO1 as potential therapeutic agent in high risk prostate cancer

Be-RALP study: The effect of adjuvant treatment on quality of life, erectile function and continence

Ion feedback suppression in time projection chambers

PEACE V–Salvage Treatment of oligorecurrent nodal prostate cancer metastases (STORM): 24-months toxicity results of a randomized phase II trial

A0644 - PEACE V–Salvage Treatment of oligorecurrent nodal prostate cancer metastases (STORM): 24-months toxicity results of a randomized phase II trial

Ambient-Processable High Capacitance Hafnia-Organic Self-Assembled Nanodielectrics

Suchergebnisse filtern